

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

(1) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG (2) CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND (3) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board (the “**Board**”) of directors (the “**Directors**”) of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that with effect from September 5, 2022, the address of the principal place of business of the Company in Hong Kong is changed to 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong.

CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT

The Board further announces that due to personal work arrangement, Mr. Kai Cheong Willie Cheung (“**Mr. Cheung**”) has tendered his resignation as (i) the joint company secretary of the Company (the “**Joint Company Secretary**”); (ii) the authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) the authorised representative for the service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from September 5, 2022. Mr. Quanwei Yuan (“**Mr. Yuan**”) will remain as the other Joint Company Secretary.

Mr. Cheung has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board further announces that Ms. Kwan Sau In (“**Ms. Kwan**”) has been appointed as the Joint Company Secretary, the Authorised Representative and the Process Agent with effect from September 5, 2022.

The respective biographical details of Ms. Kwan and Mr. Yuan are as follows:

Ms. Kwan is a manager of corporate services of Tricor Services Limited. She has over 8 years of experience in corporate secretarial and compliance matters for Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Kwan is an associate member of each of The Hong Kong Chartered Governance Institute (formerly The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute in the United Kingdom and obtained a bachelor’s degree of business administration in corporate administration.

Mr. Yuan is the chief financial officer of the Company. Mr. Yuan joined the Group in January 2021. He is primarily responsible for overseeing the financial management and corporate development of the Group.

Mr. Yuan has more than 10 years of corporate finance and financial market related experience. Prior to joining the Company, he served as an executive director and the chief financial officer for Souche Holding from March 2018. Between November 2016 to March 2018, Mr. Yuan joined Simcere Pharmaceutical Group as the vice president, overseeing capital market and business development. Before that, Mr. Yuan worked for investment banking division for various multi-national investment bank, namely Credit Suisse Group AG, Deutsche Bank AG and Bank of America & BofA Securities (formerly Bank of America Merrill Lynch) from July 2009 to October 2016. His last function with Bank of America & BofA Securities is director in investment banking division.

Mr. Yuan received a bachelor’s degree in civil engineering from Tongji University in the People’s Republic of China in July 2001, a master’s degree in civil engineering from the University of Cincinnati in the United States in March 2005 and a M.B.A. degree from the University of Chicago in the United States in June 2009.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the waiver granted to the Company by the Stock Exchange (the “**Waiver**”) from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Mr. Yuan to act as a company secretary for a three-year period from the date of the Company’s listing on the Main Board of the Stock Exchange (i.e. July 5, 2021) (the “**Waiver Period**”), on the condition that the Company appoints Mr. Cheung, who meets the requirement under Rule 3.28 of the Listing Rules, as a Joint Company Secretary to assist Mr. Yuan during the Waiver Period; and the Waiver can be revoked if there are material breaches of the Listing Rules by the Company. Relevant details of the Waiver were disclosed in the prospectus of the Company dated June 22, 2021.

Given the condition of the Waiver could no longer be fulfilled following the resignation of Mr. Cheung, the Company has applied and the Stock Exchange has granted a new waiver (the “**New Waiver**”) to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver (i.e. from the date of the appointment of Ms. Kwan as a Joint Company Secretary (being September 5, 2022) to July 4, 2024) (the “**New Waiver Period**”) on the conditions that (i) Mr. Yuan must be assisted by Ms. Kwan during the New Waiver Period; and (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the New Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Mr. Yuan, having had the benefit of the assistance from Ms. Kwan during the New Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Board would like to take this opportunity to express its gratitude to Mr. Cheung for his valuable contribution to the Company during his tenure of service, and welcome Ms. Kwan on her new appointment.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, September 5, 2022

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.